Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of hematology deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hematology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in hematology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of hematology deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Hematology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of hematology deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hematology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in hematology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of hematology deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Benefits
Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse hematology collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
Hematology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hematology trends and structure of deals entered into by leading biopharma companies worldwide.Hematology Collaboration and Licensing Deals includes:
- Trends in hematology dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of hematology deal records covering pharmaceutical and biotechnology
- The leading hematology deals by value
- Most active hematology licensing dealmakers
In Hematology Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Hematology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in hematology dealmaking
Chapter 3 - Financial deal terms for hematology partnering
Chapter 4 - Leading hematology deals and dealmakers
Chapter 5 - Hematology contract document directory
Chapter 6 - Hematology dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2seventy bio
- Abbvie
- Acceleron Pharma
- Acrotech Biopharma
- Adaptive Biotechnologies
- AffaMed Therapeutics
- AgeX Therapeutics
- Agios Pharmaceuticals
- AkaRx
- Akebia Therapeutics
- Albert Einstein College of Medicine
- Alfasigma
- Amag Pharmaceuticals
- American Society of Hematology
- Antengene
- Anthos Therapeutics
- Apellis Pharmaceuticals
- Aplagon
- Aplastic Anemia & MDS International Foundation
- Aptahem
- APT Therapeutics
- Arbor Biotechnologies
- ArcherDX
- Aruvant Sciences
- ASC Therapeutics
- ASKA Pharmaceuticals
- Association for the Advancement of Blood & Biotherapies
- AstraZeneca
- Atomwise
- Audaire Health
- Babson Diagnostics
- Baxalta
- Baxter International
- Bayer
- Bayer Healthcare
- Beam Therapeutics
- Becton Dickinson
- Beijing InnoCare Pharma
- Beth Israel Deaconess Medical Center
- Beyondspring Pharmaceuticals
- Bicycle Therapeutics
- Bill and Melinda Gates Foundation
- Bioceros
- BIOCORP
- Biolog-id
- BioMatrix Specialty Pharmacy
- Biomed Elements
- Bioverativ
- Blau Pharma
- Blood Centers of America
- Bluebird Bio
- Bluejay Diagnostics
- Boryung Pharmaceutical
- Bristol-Myers Squibb
- Brooklyn ImmunoTherapeutics
- C-Bridge Capital
- Cadila Pharmaceuticals
- California Institute for Regenerative Medicine
- Calithera Biosciences
- CAMP4 Therapeutics
- Cardiovascular Systems
- Celgene
- Cell Point
- Centogene
- Children's Hospital of Philadelphia
- Children's Hospital Of Wisconsin
- Children's Minnesota
- China Medical System
- Cincinnati Children’s Hospital Medical Center
- City of Hope
- Civica Rx
- CJ Corp
- Codexis
- Comercializadora BioRenal
- CRISPR Therapeutics
- CSL Behring
- CSL Plasma
- Curetis
- CytoSorbents
- Daiichi Sankyo
- Department of Defense
- Dialco Medical
- Diffusion Pharmaceuticals
- Disc Medicine
- Domainex
- Dong-A Pharmaceutical
- Drawbridge Health
- Drogsan Pharmaceuticals
- Duke University
- Eddingpharm
- Editas Medicine
- Eisai
- Emendo Biotherapeutics
- Enzyre
- EpiDestiny
- Ergomed
- Esperion Therapeutics
- European Medicines Agency
- Evive Biotechnology
- Ewopharma
- ExCellThera
- Expression Therapeutics
- ExThera Medical
- Factor Bioscience
- Feinstein Institute for Medical Research
- Fibriant
- Fibrogen
- Foresee Pharmaceuticals
- Forty Seven
- Foundation for Innovative New Diagnostics
- Fresenius Medical Care
- Fulcrum Therapeutics
- GC Pharma
- GE Healthcare
- Genentech
- Genexine
- GenVec
- German Federal Ministry of Education and Research
- Global Blood Therapeutics
- Golden Meditech
- Greiner Bio-One
- Grifols
- GSK
- Haematologic Technologies
- HanAll Pharmaceuticals
- Healthcare Royalty Partners
- Hemanext
- HitGen
- Homology Medicines
- Immunome
- Incyte
- Infomed
- Inmagene Biopharmaceuticals
- Innova Vascular
- Institute for Genome Statistics and Bioinformatics
- Institute of Hematology and Blood Transfusion
- Institute of Human Genetics
- Intas Pharmaceuticals
- Intellia Therapeutics
- inviCRO
- Ionis Pharmaceuticals
- Irish Haemophilia Society
- Jasper Therapeutics
- Jazz Pharmaceuticals
- JEIL Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Kaleido Biosciences
- Kamada
- Kedrion Biopharma
- Keros Therapeutics
- Kiromic Biopharma
- Kissei Pharmaceutical
- Knight Therapeutics
- La Jolla Pharmaceutical
- LaNova Medicines
- Lee's Pharmaceutical
- LogicBio Therapeutics
- Loop Medical
- LUNAC Therapeutics
- Mabwell Bioscience
- Magenta Therapeutics
- Massachusetts Institute of Technology
- Maxcyte
- Mayo Clinic
- MD Anderson Cancer Center
- Medical Technology Enterprise Consortium
- Medice Arzneimittel Pütter
- MedImmune
- Medison Pharma
- Menarini
- MicroHealth
- MindRank AI
- Ministry of Defence
- Molecular Templates
- Nantes University
- National Cancer Institute
- National Center for Advancing Translational Sciences (NCATS)
- National Heart
- Lung and Blood Institute
- National Hemophilia Foundation
- National Institutes of Health
- NCPC GeneTech
- Nencki Institute
- New York Blood Center
- Norgine
- Novartis
- Novellus Biopharma
- Novellus Therapeutics
- NovImmune
- Novo Nordisk
- Oak Hill Bio
- OMRF
- Onconova Therapeutics
- Orchard Therapeutics
- Otsuka
- Owkin
- Oxford BioMedica
- Pan American Cancer Treatment Centers
- PathoQuest
- PBM Capital Group
- Pfenex
- Pfizer
- PhaseBio Pharmaceuticals
- PicnicHealth
- Pieris Pharmaceuticals
- PixCell Medical
- Platelet BioGenesis
- Polifarma
- Portola Pharmaceuticals
- Poseida Therapeutics
- Precision BioSciences
- Pregene Biopharma
- Prime Therapeutics
- Protagonist Therapeutics
- Queens University
- Quercis Pharma
- Regen BioPharma
- Regeneron Pharmaceuticals
- Regenesis Biomedical
- Rigel Pharmaceuticals
- Roche
- Rocket Pharmaceuticals
- Rockwell Medical
- Roivant Sciences
- Romanian National Institute of Infectious Diseases
- Royal College of Surgeons (Ireland)
- RPRD Diagnostics
- Sage Bionetworks
- Samsung Bioepis
- Sandoz
- Sangamo Therapeutics
- Sanguina
- Science Foundation Ireland
- Seattle Childrens Research Institute
- Selecta Biosciences
- Selexis
- SERB Pharmaceuticals
- Sernova
- Seventh Sense Biosystems
- SFJ Pharmaceuticals
- Shanghai RAAS Blood Products
- Shield Therapeutics
- Shionogi
- Shire Laboratories
- Shire Pharmaceuticals
- Sidero Bioscience
- Sigilon Therapeutics
- Similis Bio
- Small Business Innovation Research
- SOPHiA Genetics
- Spark Therapeutics
- SQI Diagnostics
- SRS Life Sciences
- Strm.Bio
- Sumitomo Dainippon Pharma
- Supernus Pharmaceuticals
- Swedish Orphan Biovitrum
- Syna Therapeutics
- Syros Pharmaceuticals
- Sysmex
- Takeda Pharmaceutical
- Terumo Blood and Cell Technologies
- Therapeutic Solutions International
- TRPharm
- Turgut Ilaclari
- Uniformed Services University of the Health Sciences
- UniQure
- University Medical Center Utrecht
- University of Bonn
- University of Cincinnati
- University of Colorado
- University of Pittsburgh
- University of Texas
- Velesco
- Velico Medical
- VeriSIM Life
- Versiti Blood Research Institute
- Vertex Pharmaceuticals
- Vifor Pharma
- Vigene Biosciences
- Wanbang Biopharmaceuticals
- Wanchunbulin
- Washington University in St Louis
- Werum IT Solutions
- Western New England University
- Xenetic Biosciences
- Zealand University Hospital
- Zydus Cadila
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
